Haba LaboratoriesHABA LABORATORIES, INC.4925東証スタンダード化学FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥6 is left as operating profit. Revenue changed +0.7% from the prior year, operating profit +23.4%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | — | —× | -1.7% | —× | — |
| 2023 | — | —× | -4.7% | —× | — |
| 2024 | — | —× | -15.6% | —× | — |
| 2025 | 4.8% | 0.97× | 4.7% | 1.42× | 6.6% |
| 2026 | 6.3% | 0.98× | 6.1% | 1.35× | 8.2% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 12,909 | 12,038 | 12,324 | 12,062 | 12,141 |
| Cost of revenue | 4,114 | 3,870 | 3,921 | 3,969 | 4,055 |
| Gross profit | 8,795 | 8,169 | 8,404 | 8,093 | 8,087 |
| SG&A | 9,112 | 8,778 | 8,591 | 7,503 | 7,359 |
| Operating income | -317 | -610 | -188 | 590 | 727 |
| Pretax income | -267 | -549 | -1,843 | 636 | 850 |
| Income tax | 2 | 159 | 275 | 59 | 90 |
| Net income attributable to owners | -269 | -708 | -2,119 | 577 | 760 |
| Operating margin | -2.5% | -5.1% | -1.5% | 4.9% | 6.0% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥5.65B | ¥4.82B | ¥3.96B | ¥4.74B | ¥5.68B |
| Total assets | ¥15.7B | ¥14.7B | ¥12.4B | ¥12.3B | ¥12.5B |
| Net assets | ¥11.6B | ¥10.8B | ¥8.51B | ¥8.93B | ¥9.54B |
| Share capital | ¥696.5M | ¥696.5M | ¥696.5M | ¥696.5M | ¥696.5M |
| Property, plant and equipment | ¥4.66B | ¥4.45B | ¥2.96B | ¥2.97B | ¥2.37B |
| Intangible assets excluding goodwill | ¥346.2M | ¥315.8M | ¥0 | ¥93.4M | ¥112.7M |
| Investment securities | ¥6.5M | ¥7M | ¥11.9M | — | — |
| Current assets | ¥10.1B | ¥9.34B | ¥9.08B | ¥9.04B | ¥9.78B |
| Current liabilities | ¥2.53B | ¥2.8B | ¥2.81B | ¥2.66B | ¥2.35B |
| Short-term borrowings | ¥300M | ¥200M | ¥600M | ¥500M | ¥100M |
| Long-term borrowings | ¥1.47B | ¥1.03B | ¥1B | ¥727.7M | ¥607.5M |
| Total liabilities | ¥4.05B | ¥3.88B | ¥3.92B | ¥3.42B | ¥2.98B |
| Equity attributable to owners of parent | ¥11.6B | ¥10.8B | ¥8.5B | ¥8.93B | ¥9.54B |
| Retained earnings | ¥11.3B | ¥10.4B | ¥8.13B | ¥8.55B | ¥9.16B |
| Treasury stock | -¥1.14B | -¥1.14B | -¥1.14B | -¥1.14B | -¥1.14B |
EDINET (FSA Japan)
有価証券報告書－第43期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第42期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第41期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第40期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第39期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第38期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 48 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.